Atopic dermatitis is a common immunologic skin disease. Mild atopic dermatitis can be managed with emollients and topical therapies such as low potency topical steroids, which have a favorable safety profile. Severe atopic dermatitis, in contrast, is a challenging disease to treat. Topical therapies are typically inadequate for control of severe atopic dermatitis. When topical therapies fail, the mainstay of therapy for severe atopic dermatitis has traditionally been phototherapy or off-label use of systemic immunosuppressant treatment, yet systemic immunosuppressants all have significant potential toxicities, drug interactions, and contraindications, requiring close monitoring. Targeted biologics are therefore attractive treatment options for topical therapy-refractory cases of atopic dermatitis, with the potential to offer effective, safer treatment of uncontrolled atopic dermatitis. Dupilumab, as the only biologic therapy currently FDA-approved for atopic dermatitis, is effective for many patients, but there is need for continuing study of additional biologic therapies to address the needs of diverse patients with uncontrolled atopic dermatitis.

特应性皮炎是一种常见的免疫性皮肤病。轻度的特应性皮炎可以通过润肤剂和局部疗法（例如低效局部类固醇）进行治疗，这些药物具有良好的安全性。相反，严重的特应性皮炎是一种具有挑战性的疾病。局部治疗通常不足以控制严重的异位性皮炎。当局部治疗失败时，重症异位性皮炎的治疗传统上一直是光疗或系统免疫抑制剂治疗的标签外使用，然而全身免疫抑制剂均具有显着的潜在毒性，药物相互作用和禁忌症，需要密切监测。因此，针对性难治性特应性皮炎病例的靶向生物制剂是有吸引力的治疗选择，有可能提供有效的，更安全地治疗无法控制的特应性皮炎。Dupilumab作为目前FDA批准的用于特应性皮炎的唯一生物疗法，对许多患者有效，但是需要继续研究其他生物疗法，以解决各种无法控制的特应性皮炎患者的需求。